An interventional study of SynFlow Duro in Cardiogenic Shock, sponsored by ForQaly Medical (Shanghai) Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by ForQaly Medical (Shanghai) Co., Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Shock, Cardiogenic with a site in China — 18 open to participants now, 18 under way, none of them phase 3. Shock, Cardiogenic · China.
Among the 20 studies in Shock, Cardiogenic with a site in China, this one is the 9th largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2026, is one of 12 with no phase, reaches primary completion later than 13 of the 17 other live ones, and was the 19th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →18 of the 20 studies in Shock, Cardiogenic with a site in China are open now. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Renmin Hospital of Wuhan University · Sites in China
Ages 18+
Xiaotong Hou · Sites in China
Ages 18+
Shenzhen Core Medical Technology CO.,LTD. · Sites in China
Ages 18–80
Fujian Medical University · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 133 interventional studies indexed under Shock, Cardiogenic.
Median enrollment 82 across the 14 interventional studies, 517 across the 6 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 20 have an industry lead sponsor. The 10 most frequent:
ForQaly Medical (Shanghai) Co., Ltd is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
ForQaly Medical (Shanghai) Co., Ltd has 1 study filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
3 of the studies in Shock, Cardiogenic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06862700Xiaotong HouEffect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients | 2027-01-01 |
| NCT07380659Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySafety and Efficacy of FAP iCDC in Acute Myocardial Infarction With Cardiogenic Shock | 2027-01-30 |
| NCT07560085ForQaly Medical (Shanghai) Co., LtdCatheter-Oriented Unloading and Recovery With a Left Ventricular Assist Gear: Efficacy in Post Cardiotomy Cardiogenic Shock | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Shock, Cardiogenic with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a prospective, multicenter, single-arm clinical trial conducted in China to evaluate the efficacy and safety of a novel left ventricular assist device, SynFlow Duro system, manufactured by ForQaly Medical in the treatment of post cardiotomy cardiogenic shock.
This study is a prospective, single-arm clinical trial to be conducted in at least 2 centers in China to evaluate the efficacy an safety of a novel micro-axial flow pump for left ventricular assistance in post cardiotomy cardiogenic shock. The trial population includes those who fail to wean from cardiopulmonary bypass OR have refractory cardiogenic shock after cardiac surgery. Patients with right heart failure will be excluded. Eligible subjects will receive SynFlow system for bridging to cardiac recovery or durable cardiac therapy (cardiac transplantation or implantation of approved Ventricular Assist Device). The primary endpoint is device support success, defined as survival to 30 days post-explant or hospital discharge (whichever is longer) OR to explantation in case of bridging to durable cardiac therapies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Failure to wean from CPB is defined as failed to discontinue CPB or post-weaning CI \<2.2L/min/m2 + PCWP >15mmHg, despite optimal pre-weaning management and receiving at least one high dose inotrope.
Refractory cardiogenic shock is defined as a condition that occurs despite adequate fluid status and meets all the following criteria:
① CI\<2.2L/min/m2 + PCWP>15mmHg despite receiving at least one high dose inotrope or IABP; OR SBP \<80mmHg or MAP\<50mmHg despite receiving at least one high dose intrope + high dose norepinephrine or IABP.
② Presence of at least one signs indicating hypoperfusion: decreased mentation; cold, clammy, ashen or cyanotic extremities or skin or livedo reticularis; urine output\<30ml/h or 0.5ml/kg/h; or lactate>2mmol/L or metabolic acidosis.
- Patient has signed the form.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: SynFlow Duro
a novel micro-axial flow pump for temporary left ventricular assistance
Device support success
Cardiac recovery (survival to 30 days post-explant or hospital discharge \[which is longer\] without other mechanical support including IABP) or briging to other durable cardiac therapies (heart transplantation or implantation of approved durable ventricular assist device)
Time frame: Up to 30 days post-explant or hospital discharge (whichever is longer)
Technical success rate
Technical success is defined as successful device placement, deployment, startup and explantation without any device malfunction
Time frame: Through device explantation, up to 14 days
Cardiac index change versus baseline
Time frame: Within 24 hours after device startup
Cardiac output change versus baseline
Time frame: Within 24 hours after device startup
Pulmonary artery pressure change versus baseline
Time frame: Within 24 hours after device startup
Mean arterial pressure change versus baseline
Time frame: Within 24 hours after device startup
Central venous pressure change versus baseline
Time frame: Within 24 hours after device startup
Device support duration
Time from device startup to device explanation
Time frame: Through device explantation, up to 14 days
Time to recovery
Recovery is defined as survival to 30 days post-explant or hospital discharge (which is longer) without other mechanical support including IABP
Time frame: From device placement to 30 days post-explant or hospital discharge (whichever is longer)
Major adverse event
Defined as stroke or death
Time frame: From device placement to 30 days post-explant or hospital discharge or bridging to other durable cardiac therapies
Minor adverse event
Defined as minor or major bleeding, hemolysis, limb ischemia, requiring continuous renal placement therapy, ventricular tachycardia or fibrillation requiring cardioversion, sepsis, mechanical complications and major access vascular complications.
Time frame: From device placement to 30 days post-explant or hospital discharge or bridging to other durable cardiac therapies
Adverse event
Defined as untoward medical event occurring during the course of clinical investigation, whether or not related to the medical device.
Time frame: From device placement to 30 days post-explant or hospital discharge or bridging to other durable cardiac therapies
Serious adverse event
Defined as the event occurring during the course of clinical investigation, which leads to death or serious deterioration in the health, including a life-threatening illness or injury; a permanent impairment of a body structure or a body function; in-patient or prolonged hospitalization; medical or surgical intervention to prevent permanent impairment to a body structure or a body function; foetal distress, foetal death, congenital abnormality or birth defect, etc.
Time frame: From device placement to 30 days post-explant or hospital discharge or bridging to other durable cardiac therapies
Device deficiency
Defined as the unreasonable risk that may endanger human health and life safety in the normal use of medical devices during clinical investigations, such as labeling errors, quality problems, malfunctions, etc.
Time frame: Through device explantation, up to 14 days
Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.
Of 52 interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ForQaly Medical (Shanghai) Co., Ltd